We speculated two major reasons may account for this point: (1) the size of samples in CPTAC was small, which lead the last result not accurate; (2) through a subgroup analysis according to the ER expression, we found that high expression of SLC39A7 was significantly associated with worse OS in ER positive patients, but no significant correlation was found between SLC39A7 expression and OS of patients with ER negative BC, which was consistent with the above results. The gene discussed is SLC39A7; the disease is breast cancer.